Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin

Starting soon · Not applicable

Conditions studied: Melatonin, Breast Cancer Patients Diagnosed, Vitamin D Concentration, Doxorubicin

In brief

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

Key facts

Study ID

NCT07349459

Run by

Tanta University

People needed

90

Starts

2026-04-30

Expected to finish

2026-08-30

Last updated by the study team

2026-01-16

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age from 18 to 65 years old.
• Gender: female.
• Positive breast cancer women who are scheduled to receive Doxorubicin.
• Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.
• Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.
• Normal renal and liver function tests.

You may not qualify if…

• Pregnant or breastfeeding women.
• Women with HER-2 positive of breast cancer.
• Formerly treated with Doxorubicin.
• Patients with a known hypersensitivity to any of the used drugs.
• On other concomitant vitamins or food supplements.
• Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.
• Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction < 50%.

Where it is running

• Tanta University — Tanta, Egypt

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.